WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 562381
CAS#: 105955-01-9
Description: KS370G is an inhibitor of UUO-induced renal fibrosis markers expression. It acts by attenuating collagen deposition in the obstructed kidney and significantly lowering the expression of renal inflammatory chemokines/adhesion molecules and monocyte cells marker.
MedKoo Cat#: 562381
Name: KS370G
CAS#: 105955-01-9
Chemical Formula: C17H17NO3
Exact Mass: 283.1208
Molecular Weight: 283.327
Elemental Analysis: C, 72.07; H, 6.05; N, 4.94; O, 16.94
Synonym: KS370G; KS-370-G; KS 370 G;
IUPAC/Chemical Name: 3-(3,4-Dihydroxy-phenyl)-N-phenethyl-acrylamide
InChi Key: QOWABIXYAFJMQE-VQHVLOKHSA-N
InChi Code: InChI=1S/C17H17NO3/c19-15-8-6-14(12-16(15)20)7-9-17(21)18-11-10-13-4-2-1-3-5-13/h1-9,12,19-20H,10-11H2,(H,18,21)/b9-7+
SMILES Code: O=C(NCCC1=CC=CC=C1)/C=C/C2=CC=C(O)C(O)=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | KS370G is an inhibitor of UUO-induced renal fibrosis markers expression. |
| In vitro activity: | KS370G significantly inhibited the release of nitric oxide (NO) and the expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Treatment with KS370G also induced heme oxygenase (HO)-1 and suppressors of cytokine signaling (SOCS)-3 expression in the microglia. Reference: Mol Neurobiol. 2013 Dec;48(3):863-74. https://pubmed.ncbi.nlm.nih.gov/23801310/ |
| In vivo activity: | The results show that KS370G significantly attenuated collagen deposition in the obstructed murine kidney and inhibited UUO-induced renal fibrosis markers expression, including fibronectin, type I collagen, vimentin, and α-smooth muscle actin (α-SMA). KS370G significantly lowered the expression of renal inflammatory chemokines/adhesion molecules and monocyte cells marker (MCP-1, VCAM-1, ICAM-1 and CD11b). Reference: Eur J Pharmacol. 2015 Mar 5;750:1-7. https://pubmed.ncbi.nlm.nih.gov/25620133/ |
The following data is based on the product molecular weight 283.327 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Lu DY, Huang BR, Yeh WL, Lin HY, Huang SS, Liu YS, Kuo YH. Anti-neuroinflammatory effect of a novel caffeamide derivative, KS370G, in microglial cells. Mol Neurobiol. 2013 Dec;48(3):863-74. doi: 10.1007/s12035-013-8474-y. Epub 2013 Jun 26. PMID: 23801310. 2. Chuang ST, Kuo YH, Su MJ. KS370G, a caffeamide derivative, attenuates unilateral ureteral obstruction-induced renal fibrosis by the reduction of inflammation and oxidative stress in mice. Eur J Pharmacol. 2015 Mar 5;750:1-7. doi: 10.1016/j.ejphar.2015.01.020. Epub 2015 Jan 22. PMID: 25620133. 3. Chuang ST, Kuo YH, Su MJ. Antifibrotic effects of KS370G, a caffeamide derivative, in renal ischemia-reperfusion injured mice and renal tubular epithelial cells. Sci Rep. 2014 Jul 24;4:5814. doi: 10.1038/srep05814. PMID: 25056456; PMCID: PMC4108915. |
| In vitro protocol: | 1. Lu DY, Huang BR, Yeh WL, Lin HY, Huang SS, Liu YS, Kuo YH. Anti-neuroinflammatory effect of a novel caffeamide derivative, KS370G, in microglial cells. Mol Neurobiol. 2013 Dec;48(3):863-74. doi: 10.1007/s12035-013-8474-y. Epub 2013 Jun 26. PMID: 23801310. |
| In vivo protocol: | 1. Chuang ST, Kuo YH, Su MJ. KS370G, a caffeamide derivative, attenuates unilateral ureteral obstruction-induced renal fibrosis by the reduction of inflammation and oxidative stress in mice. Eur J Pharmacol. 2015 Mar 5;750:1-7. doi: 10.1016/j.ejphar.2015.01.020. Epub 2015 Jan 22. PMID: 25620133. 2. Chuang ST, Kuo YH, Su MJ. Antifibrotic effects of KS370G, a caffeamide derivative, in renal ischemia-reperfusion injured mice and renal tubular epithelial cells. Sci Rep. 2014 Jul 24;4:5814. doi: 10.1038/srep05814. PMID: 25056456; PMCID: PMC4108915. |
1: Chuang ST, Kuo YH, Su MJ. KS370G, a caffeamide derivative, attenuates unilateral ureteral obstruction-induced renal fibrosis by the reduction of inflammation and oxidative stress in mice. Eur J Pharmacol. 2015 Mar 5;750:1-7. doi: 10.1016/j.ejphar.2015.01.020. Epub 2015 Jan 22. PubMed PMID: 25620133.
2: Chuang ST, Kuo YH, Su MJ. Antifibrotic effects of KS370G, a caffeamide derivative, in renal ischemia-reperfusion injured mice and renal tubular epithelial cells. Sci Rep. 2014 Jul 24;4:5814. doi: 10.1038/srep05814. PubMed PMID: 25056456; PubMed Central PMCID: PMC4108915.
3: Lu DY, Huang BR, Yeh WL, Lin HY, Huang SS, Liu YS, Kuo YH. Anti-neuroinflammatory effect of a novel caffeamide derivative, KS370G, in microglial cells. Mol Neurobiol. 2013 Dec;48(3):863-74. doi: 10.1007/s12035-013-8474-y. Epub 2013 Jun 26. PubMed PMID: 23801310.
4: Weng YC, Chuang CF, Chuang ST, Chiu HL, Kuo YH, Su MJ. KS370G, a synthetic caffeamide derivative, improves left ventricular hypertrophy and function in pressure-overload mice heart. Eur J Pharmacol. 2012 Jun 5;684(1-3):108-15. doi: 10.1016/j.ejphar.2012.03.029. Epub 2012 Mar 29. PubMed PMID: 22484506.
5: Weng YC, Chiu HL, Lin YC, Chi TC, Kuo YH, Su MJ. Antihyperglycemic effect of a caffeamide derivative, KS370G, in normal and diabetic mice. J Agric Food Chem. 2010 Sep 22;58(18):10033-8. doi: 10.1021/jf1024246. PubMed PMID: 20804127.
